Is Parabilis Medicines, Inc. (PBLS) a Buy, Sell, or Hold?
NASDAQ : PBLS
Parabilis Medicines, Inc.
$27.31 USD
-$2.24 (-7.58%)
- Volume
- 641.88K
- Average Volume
- 1M
- Market Capitalization
- $89.44M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- $40.00
- Year High
- $34.47
- Year Low
- $24.51
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
Company Overview
NASDAQ
Mathai Mammen
Biotechnology
Healthcare
PBLS
145
US
USD
Liquidity Metrics
Sales & Valuation
-$
Profitability
-$
%
%
%
%
P/E Metrics
Analyst Price Target & Rating
$40.00
$40.00
$40.00
0/5
0 Analysts
-31.73%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Fawzi Benzaghou | Chief Medical Officer |
| Mohammed Fawzi Benzaghou | Chief Medical Officer |
| Jonathan Hurov | Executive Vice President of Discovery Biology |
| Mathai Mammen | CEO, President, Treasurer & Chairman |
| Rohin Mhatre | Chief Technical Operations Officer |
| Jianing Di | VP of International R&D and Corporate Development |
| John McGee | Scientific Co-Founder, Executive Vice President & Head of Platform |
| Thomas Kotarakos | Chief Financial Officer |
| Thomas Rodolpho Kotarakos | Chief Financial Officer |
| Kristen Stants | Chief People Officer |
| Marie Nguyen | Senior VP & Head of Clinical Development |
| Teresa L. Jurgensen | Executive VP, Secretary & General Counsel |
Poll Results
No votes yet today — be the first to share your view!
About Parabilis Medicines, Inc. (NASDAQ:PBLS) Stock
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA. ...
2026-07-06 07:52:28
Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. With second-quarter earnings starting this week, and with all of the major indices trading at or near all-time highs, you... Here Are Monday's Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More
2026-07-06 07:11:19
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
2026-06-27 20:00:00
Parabilis saw its shares rise by more than SpaceX's shares did after its IPO. That doesn't mean it's guaranteed to succeed.
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
2026-06-20 12:41:50
Director Alan Sebulsky acquired 17,500 shares for $474,000, based on a weighted average purchase price of $27.06 per share. This activity increased his ownership to 30,000 shares, held through an entity he controls.
2026-06-11 16:05:00
CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the closing of its upsized initial public offering of an aggregate 38,525,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 5,025,000 additional shares, at an initial public offering price of $20.00 per share. All of the shares of common stock were offered by Parabilis. Parabilis' common stock began trading on the Nasdaq Global Select Market on June 10, 2026 under the ticker symbol “PBLS”.
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
2026-06-09 20:22:00
CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the pricing of its upsized initial public offering of 33,500,000 shares of its common stock at a price to the public of $20.00 per share. In addition, Parabilis has granted the underwriters a 30-day option to buy an additional 5,025,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.
Parabilis Medicines aims to raise $633 million in upsized US IPO
2026-06-09 06:16:20
Biopharmaceutical company Parabilis Medicines said on Tuesday it was aiming to raise as much as $633.3 million in its upsized initial public offering in the U.S.
Frequently Asked Questions
-
What is the current Parabilis Medicines, Inc. (PBLS) stock price?
-
Parabilis Medicines, Inc.(NASDAQ:PBLS) stock price is $27.31 in the last trading session. During the trading session, PBLS stock reached the peak price of $34.47 while $24.51 was the lowest point it dropped to. The percentage change in PBLS stock occurred in the recent session was --7.58% while the dollar amount for the price change in PBLS stock was -$2.24.
-
PBLS's industry and sector of operation?
-
The NASDAQ listed PBLS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PBLS?
-
Fawzi Benzaghou | Chief Medical Officer
Mohammed Fawzi Benzaghou | Chief Medical Officer
Jonathan Hurov | Executive Vice President of Discovery Biology
Mathai Mammen | CEO, President, Treasurer & Chairman
Rohin Mhatre | Chief Technical Operations Officer -
How many employees does PBLS have?
-
Number of PBLS employees currently stands at 145. PBLS operates from 30 Acorn Park Dr, Cambridge, MA 02140, US.
-
Link for PBLS official website?
-
Official Website of PBLS is: http://www.parabilismed.com
-
How do I contact PBLS?
-
PBLS could be contacted at phone #None and can also be accessed through its website. PBLS operates from 30 Acorn Park Dr, Cambridge, MA 02140, US.
-
How many shares of PBLS are traded daily?
-
The average number of PBLS shares traded daily for last 3 months was 1M.
-
What is the market cap of PBLS currently?
-
The market value of PBLS currently stands at $89.44M with its latest stock price at $27.31